

(Formely Known as Adi Rasayan Limited)

CIN: L24231MH1992PLC323914

Date: 31st May, 2021

To,
General Manager,
Department of Corporate Services,
BSE Limited.,
P J Towers, Dalal Street,
Mumbai- 400 001.

Dear Sir/ Madam

Subject: Media Release.

Reference: Generic Pharmasec Limited [The Company] enters into agreement with Abbott Point of Care Inc (APOC).

BSE: Scrip Code: 531592

With reference to the above captioned subject, we are pleased to inform your goodself that the Company has executed an agreement with APOC the medical & diagnostics devices division of Abbott, world's 8th largest Pharma Company, for the distribution, marketing and promotion of the entire range of products by APOC in the entire country of India.

In this respect we are enclosing herewith a Media Release containing a detailed summary for your information and records.

You are requested to take the same on your records and oblige.

Thanking you,

Yours faithfully,

For Generic Pharmasec Limited

(Formerly known as Adi Rasayan Limited)

Mr. Dollar Azad

Director

DIN 08490484

9

104 & 105 1st Floor Gundecha Industrial Premises Co-op Soc. Ltd., Akurli Road, Kandivali (East) Mumbai - 400101.

+91-86555 50242

compliance@genpharmasec.com info@genpharmasec.com

www.genpharmasec.com



(Formely Known as Adi Rasayan Limited)
CIN: L24231MH1992PLC323914

2 104 & 105 1st Floor Gundecha Industrial Premises Co-op Soc. Ltd., Akurli Road, Kandivali (East) Mumbai - 400101.

+91-86555 50242

compliance@genpharmasec.com info@genpharmasec.com

www.genpharmasec.com

Generic Pharmasec Enters Into Agreement with Abbott Point of Care (APOC):-

The company has entered into an agreement with Abbott Point of Care (APOC) Inc, the medical & diagnostics devices division of Abbott, the world's 8th largest Pharma Company, for the distribution, marketing and promotion of the entire range of products by APOC in the entire country of India. The agreement has just now become effective and covers the entire length & breadth of the country.

The agreement will increase the annual diagnostic tests supplied by Generic Pharmasec Limited by more than two-fold to an upwards of 1 million test annually. It will also improve the Product Margin on the Abbott Point of Care products by Generic Pharmasec by 2.5% which is almost 50% higher than current margins.

Generic Pharmasec Limited will now increase its focus on creating high value propositions for all hospitals in India for all their Critical Diagnostic Requirements. To Increase the footprint in the country & improve access to Critical Diagnostic Solutions in Tier-2 & Tier-3 towns, Generic Pharmasec Limited will appoint 15 new sub-distributors over the course of the next 24 months in such identified towns across the country.

We aim to increase i-STAT devices penetration by at least 1,000 additional hospital set-ups in the next 24 months by creating long-term strategies for Marketing & Promotion with this unique partnership with Abbott Point of Care Inc.

About Abbott Laboratories:-

Abbott Laboratories is an American worldwide health care company. It has 74,000 employees and operates in more than 150 countries. The company headquarters are in Lake Bluff, Illinois. In 2020, revenues were \$35 billion.

Abbott has a broad range of branded generic pharmaceuticals, medical devices, diagnostics and nutrition products. The company's in-vitro diagnostics business performs immunoassays and blood screening. Its medical tests and diagnostic instrument systems are used worldwide by hospitals, laboratories, blood banks, and physician offices to diagnose and monitor diseases such as HIV, hepatitis, cancer, heart failure and metabolic disorders, as well as assess other indicators of health. In 1985, the company developed the first HIV blood-screening test.

Abbott point of care solutions worldwide has improved patient care by transforming diagnostic experience and improving the flow of critical information by making it available when and where it is needed. Hence it is ideal for use in any healthcare setting including Urban and rural health care centres, acute health care clinics, critical care areas, Mobile Diagnostics and Ambulances (Air and Road).



About Abbott in India

Established in 1910, Abbott in India is one of the country's oldest and most admired healthcare companies. The company provides consumers with a diverse range of diagnostics solutions, medical devices, nutritional products and established pharmaceuticals that span the continuum of care.

With over 14,000 employees in India and extensive local knowledge, the company offers relevant solutions that ensure the healthcare needs of consumers, patients, doctors, hospitals, blood banks and laboratories are being met throughout both rural and urban areas.

Positioned as a market leader in pharmaceuticals, nutrition, devices and diagnostics, key brands occupy the top positions in relevant categories with over 400 trusted pharmaceutical brands; a variety of nutritional products for infants, children, active adults and people with special dietary needs; medical devices, including blood glucose meters, vascular devices and a range of diagnostics solutions.

About Generic Pharmasec Limited:

Incorporated in 1992, Generic Pharmasec Limited started as a manufacturer and trader of organic & inorganic chemicals, dyes & pigments. Since 2018, the Company is engaged in the business of manufacturers, buyers, sellers, retailers and distributing agents of and dealers in all kinds of pharmaceutical, medicinal and medicated preparations. The company has decided to shift its core competence to the lucrative medical & diagnostics device segment. Headquartered in Mumbai, the company plans to rapidly expand to all the four major metros within the next 12 months & increase its product portfolio under the said segment over the period of time.

For more details please visit: www.genpharmasec.com
For Further Information you may please contact:
Mr. Dollar Azad Chheda,
Whole Time Director
Generic Pharmasec Limited
Email: compliance@genpharmasec.com

Contact Number: 86555 50242 Website: www.genpharmasec.com

Disclaimer: Certain statements in this document may be forward-looking statements. Such forward-looking statements are subject to certain risks and uncertainties like regulatory changes, local political or economic developments, and many other factors that could cause our actual results to differ materially from those contemplated by the relevant forward-looking statements. Further, past performance is not necessarily indicative of future results. Given these risks, uncertainties and other risk factors, viewers are cautioned not to place undue reliance on these forward-looking statements. The Company will not be in any way responsible for any action taken based on such statements and undertakes no obligation to publicly update these forward-looking statements to reflect subsequent events or circumstances.



